Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00887809 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT00887809: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00887809 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00887809, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel and bevacizumab has on sarcoma.
Interventions
- DRUG bevacizumab
- DRUG docetaxel
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00887809
The ClinicalTrials.gov registry entry for NCT00887809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which bevacizumab is the first listed.
NCT00887809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00887809 about?
NCT00887809 is a clinical study titled "Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes". The purpose of this study is to test whether an experimental drug called bevacizumab given together with gemcitabine and docetaxel, a standard chemotherapy regimen for sarcoma, can help sarcoma patients. This trial will examine what effects, good and/or bad the combination of gemcitabine, docetaxel ...
What is the current status of trial NCT00887809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2009-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00887809?
The interventions under investigation include: bevacizumab (DRUG), docetaxel (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00887809?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.